# US 2016/0354485 A1 · 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354485 A1
- Document ID: US20160354485A1
- Status: Published application
- Kind: A1
- Application number: 15/182,444
- Filed: 2016-06-14
- Published: 2016-12-08
- Earliest claimed: 2013-12-16
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: John A. Flygare; Thomas H. Pillow; Brian Safina; Vishal Verma; BinQing Wei; William Denny; Anna Giddens; Ho Lee; Guo-Liang Lu; Christian Miller; Gordon Rewcastle; Moana Tercel; Muriel Bonnet
- Web page: https://patentgrep.com/patent/US20160354485A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61P 35/00: Antineoplastic agents
- C07D 209/60: Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
- C07D 403/14: containing three or more hetero rings
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.

## Claims

### Claim 1

An antibody-drug conjugate compound having the formula:
Ab-(L-D)p
wherein:
Ab is an antibody;
L is a linker having the formula:
-Str-(Pep)m-(Sp)n-
where Str is a stretcher unit covalently attached to the antibody; Pep is an optional peptide unit of two to twelve amino acid residues, Sp is an optional spacer unit covalently attached to a dimer drug moiety, and m and n are independently selected from 0 and 1;
p is an integer from 1 to 8;
D is the dimer drug moiety having the formula:
where
R1 is selected from H, P(O)3H2, C(O)NRaRb, or a bond to L;
R2 is selected from H, P(O)3H2, C(O)NRaRb, or a bond to L;
Ra and Rb are independently selected from H and C1-C6 alkyl optionally substituted with one or more F,
or Ra and Rb form a five or six membered heterocyclyl group;
T is a tether group selected from C3-C12 alkylene, Y, (C1-C6 alkylene)-Y—(C1-C6 alkylene), (C1-C6 alkylene)-Y—(C1-C6 alkylene)-Y—(C1-C6 alkylene), (C2-C6 alkenylene)-Y—(C2-C6 alkenylene), and (C2-C6 alkynylene)-Y—(C2-C6 alkynylene);
where Y is independently selected from O, S, NR1, aryl, and heteroaryl;
where alkylene, alkenylene, aryl, and heteroaryl are independently and optionally substituted with F, OH, O(C1-C6 alkyl), NH2, NHCH3, N(CH3)2, OP(O)3H2, or C1-C6 alkyl, where alkyl is optionally substituted with one or more F;
or alkylene, alkenylene, aryl, and heteroaryl are independently and optionally substituted with a bond to L;
D′ is a drug moiety selected from:
where the wavy line indicates the site of attachment to T;
X1 and X2 are independently selected from O and NR3, where R3 is selected from H and C1-C6 alkyl optionally substituted with one or more F;
R4 is H, CO2R, or a bond to L, where R is C1-C6 alkyl or benzyl; and
R5 is H or C1-C6 alkyl; wherein the antibody binds to Napi2b and
the antibody comprises three light chain hypervariable regions (HVR-L1, HVR-L2 and HVR-L3) and three heavy chain hypervariable regions (HVR-H1, HVR-H2 and HVR-H3) wherein:
HVR-L1 comprises the amino acid sequence of SEQ ID NO:75;
HVR-L2 comprises the amino acid sequence of SEQ ID NO:76;
HVR-L3 comprises the amino acid sequence of SEQ ID NO:77.
HVR-H1 comprises the amino acid sequence of SEQ ID NO:78;
HVR-H2 comprises the amino acid sequence of SEQ ID NO:79; and
HVR-H3 comprises the amino acid sequence of SEQ ID NO:80; or
the antibody comprises a light chain hypervariable region comprising the amino acid sequence of SEQ ID NO:81 or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:82.

### Claim 2 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein Str has the formula:
wherein R6 is selected from the group consisting of C1-C10 alkylene, C3-C8 carbocyclyl, O—(C1-C8 alkyl), arylene, C1-C10 alkylene-arylene, arylene-C1-C10 alkylene, C1-C10 alkylene-(C3-C8 carbocyclyl), (C3-C8 carbocyclyl)-C1-C10 alkylene, C3-C8 heterocyclyl, C1-C10 alkylene-(C3-C8 heterocyclyl), (C3-C8 heterocyclyl)-C1-C10 alkylene, C1-C10 alkylene-C(O)N(R8)—C2-C6 alkylene-N(R8), N(R8)—(C2-C6 alkylene), and (CH2CH2O)r—CH2; where R8 is H or C1-C6 alkyl, and r is an integer ranging from 1 to 10.

### Claim 3 (depends on 2)

The antibody-drug conjugate compound of claim 2 wherein R6 is (CH2)5.

### Claim 4 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein m is 0 and n is 0.

### Claim 5 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein m is 0 and n is 1.

### Claim 6 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein Str has the formula:
wherein R7 is selected from C1-C10 alkylene, C1-C10 alkylene-O, N(R8)—(C2-C6 alkylene)-N(R8), N(R8)—(C2-C6 alkylene), and (CH2CH2O)r—CH2; where R8 is H or C1-C6 alkyl, and r is an integer ranging from 1 to 10.

### Claim 7 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein Str has the formula:
wherein R9 is selected from C1-C10 alkylene, C1-C10 alkylene-O, (C2-C6 alkylene)-N(R8), and (CH2CH2O)r—CH2; where R8 is H or C1-C6 alkyl, and r is an integer ranging from 1 to 10.

### Claim 8 (depends on 7)

The antibody-drug conjugate compound of claim 7 wherein L forms a disulfide bond with a cysteine amino acid of the antibody, and R9 is C2-C6 alkylene-O where alkylene is optionally substituted with F, OH, O(C1-C6 alkyl), NH2, NHCH3, N(CH3)2, OP(O)3H2, or C1-C6 alkyl, where alkyl is optionally substituted with one or more F.

### Claim 9 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein m is 1 and n is 1.

### Claim 10 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein m is 1 and Pep comprises two to twelve amino acid residues independently selected from glycine, alanine, phenylalanine, lysine, arginine, valine, and citrulline.

### Claim 11 (depends on 10)

The antibody-drug conjugate compound of claim 10 wherein Pep is valine-citrulline.

### Claim 12 (depends on 1)

The antibody-drug conjugate compound of claim 1 wherein n is 1 and Sp comprises para-aminobenzyl or para-aminobenzyloxycarbonyl.

### Claim 13 (depends on 9)

The antibody-drug conjugate compound of claim 9 having the formula:
where AA1 and AA2 are independently selected from an amino acid side chain; p is an integer from 1 to 8.

### Claim 14 (depends on 13)

The antibody-drug conjugate compound of claim 13 wherein the amino acid side chain is independently selected from H, —CH3, —CH2(C6Hs), —CH2CH2CH2CH2NH2, —CH2CH2CH2NHC(NH)NH2, —CHCH(CH3)CH3, or —CH2CH2CH2NHC(O)NH2.

### Claim 15 (depends on 14)

The antibody-drug conjugate compound of claim 14 having the formula:

### Claim 16 (depends on 13)

The antibody-drug conjugate compound of claim 13 having the formula:

### Claim 17 (depends on 15)

The antibody-drug conjugate compound of claim 15 having the formula:

### Claim 18 (depends on 9)

The antibody-drug conjugate compound of claim 9 having the formula:

### Claim 19 (depends on 18)

The antibody-drug conjugate compound of claim 18 having the formula:

### Claim 20 (depends on 9)

The antibody-drug conjugate compound of claim 9 having the formula:

### Claim 21 (depends on 20)

The antibody-drug conjugate compound of claim 20 having the formula:

### Claim 22 (depends on 20)

The antibody-drug conjugate compound of claim 20 having the formula:
where R7 is independently selected from H and C1-C12 alkyl.

### Claim 23 (depends on 1)

The antibody-drug conjugate compound of claim 1 where Ra and Rb form a five or six membered heterocyclyl group selected from N-methylpiperazinyl, morpholinyl, piperidyl, or pyrrolidinyl.

### Claim 24 (depends on 1)

The antibody-drug conjugate compound of claim 1 where T is C3-C5 alkylene.

### Claim 25 (depends on 24)

The antibody-drug conjugate compound of claim 24 where T is selected from (CH2)3, (CH2)4 or (CH2)5.

### Claim 26 (depends on 1)

The antibody-drug conjugate compound of claim 1 where T is (C1-C6 alkylene)-Y—(C1-C6 alkylene), where Y is phenyl substituted with a bond to L.

### Claim 27 (depends on 1)

The antibody-drug conjugate compound of claim 1 where T is (C2-C6 alkenylene)-Y—(C2-C6 alkenylene), where Y is phenyl substituted with a bond to L.

### Claim 28 (depends on 1)

The antibody-drug conjugate compound of claim 1 where Y is selected from phenyl, pyridyl, 1-methyl-1H-benzo[d]imidazole, or [1,2,4]triazolo[1,5-a]pyridine.

### Claim 29 (depends on 1)

The antibody-drug conjugate compound of claim 1 where D′ is:

### Claim 30 (depends on 1)

The antibody-drug conjugate compound of claim 1 where D′ is:

### Claim 31 (depends on 1)

The antibody-drug conjugate compound of claim 1 where D′ is:

### Claim 32 (depends on 1)

A pharmaceutical composition comprising the antibody-drug conjugate compound of claim 1, and a pharmaceutically acceptable carrier, glidant, diluent, or excipient.

### Claim 33 (depends on 32)

A method of treating cancer comprising administering to a patient a therapeutically-effective amount of the pharmaceutical composition of claim 32.

### Claim 34 (depends on 32)

A kit for treating cancer, comprising:
a) the pharmaceutical composition of claim 32; and
b) instructions for use.
